安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Homepage - GRAIL
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
- Multi-cancer early detection - GRAIL
GRAIL uses advanced machine learning algorithms and pattern recognition to “read” methylation patterns Using these two principles, the Galleri test has three scientific steps: Extract and sequence the DNA fragments from the blood to “read” the methylation patterns (assay)
- GRAIL Reports First Quarter 2025 Financial Results - GRAIL, Inc.
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
- Careers - GRAIL
Everything we do is guided by our mission to detect cancer early, when it can be cured We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
- Press Releases - GRAIL
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research Annual Meeting 2023
- GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early . . .
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
- Diagnostic Aid for Cancer - GRAIL
GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Diagnostic Aid for Cancer We are developing our diagnostic aid for cancer (“DAC”) test to accelerate diagnostic resolution for patients with non-specific signs and symptoms, but with a clinical suspicion of cancer
- GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
MENLO PARK, Calif — Feb 20, 2025 — GRAIL, Inc (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates
|
|
|